IceCure Medical Ltd Stock News

IceCure Medical (ICCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Demonstrates public health importance of assessing ProSense®'s potential to offer optimal treatment that benefits women with early-stage breast cancer Patients, patient advocacy groups, doctors, and

IceCure Medical Ltd (NASDAQ:ICCM ) Q1 2024 Earnings Conference Call May 28, 2024 11:00 AM ET Company Participants Michael Polyviou - Investor Relations Eyal Shamir - Chief Executive Officer Tlalit Bus

30% sales growth reflects continued adoption of ProSense® in the U.S. and other global markets Major milestones achieved: - Completion of landmark ICE3 trial for breast cancer - Positive final ICE3

CAESAREA, Israel, May 21, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that

CAESAREA, Israel , May 21, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that

CAESAREA, Israel , May 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that

Study published in the peer reviewed journal Breast Cancer Excellent cosmetic outcomes, high degree of patient satisfaction, and improved quality of life post-cryoablation Strategic distribution part

IceCure Medical (ICCM) submits final ICE data along with multiple sub-analysis to the FDA seeking approval for marketing authorization for treating early-stage breast cancer.

Data presentation at highly influential American Society of Breast Surgeons ("ASBrS") Annual Meeting by Dr. Richard Fine wins Scientific Impact Award as voted by breast surgeons  President-Elect of t

IceCure Medical Ltd. (NASDAQ:ICCM ) Q4 2023 Earnings Conference Call April 3, 2024 10:00 AM ET Company Participants Michael Polyviou - EVC Group, Investor Relations Eyal Shamir - Chief Executive Offic

Conference call to be held today at 10:00 am Eastern Time; Focus on U.S. market for ProSense® in breast cancer indication CAESAREA, Israel , April 3, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq

Continuous innovation as a global leader in minimally invasive liquid-nitrogen based cryoablation systems CAESAREA, Israel , April 2, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure

Overview of U.S. Commercial Strategy will be Discussed on Conference Call CAESAREA, Israel , March 27, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer

Expects to submit full dataset to the FDA in April for marketing authorization of ProSense® for minimally invasive treatment of early-stage breast cancer Study represents largest cryoablation study o